SlideShare a Scribd company logo
1 of 12
Compensation Given In
Clinical Trail
 Presented By : Neha Singh
M.pharm 1st year
Clinical Research
 As per rule 122 DAB of drug and cosmetics rule
1945, in case of clinical trial related injury other
than death, the trial subject is entitled to pay for
financial compensation. The sponsor or his
representative is required to pay the financial
compensation as per the order of DCGI. As per the
rule, the financial compensation will be over and
above the expenses incurred on the medical
management of the trial subject.
 The appendix X11 of schedule Y of D&C rules
prescribes the procedure for processing the report
of the serious adverse events including the death
to arrive at the cause of death/injury to the subject
and to decide the quantum of the compensation.
 The independent expert committee constituted for
examination od sae of death has already devised a
formulae being followed for determining the
quantum of compensation in case of clinical trail
related death.
 Another committee was constituted in march 2014
under the chairmanship of shri R.K Jain, the
additional secretory and director general (CGHS),
ministry of health & family welfare, government of
India to deliberate and work out a formulae to be
followed to determine the quantum of
compensation in case of clinical trial related injury.
Compensation formulae
(clinical trial)
 As per the rule , the financial compensation will be
over and above the expenses incurred on the
medical management of the trial subject.
 In case of clinical trial related sae of death, the
DCGI will decide the quantum of compensation
after considering the recommendation of
independent expert committee constituted for the
purpose.
 The DCGI will decide the quantum of
compensation considering the report of the
investigator, sponsor, and the ethics committee .
 Formulae to determine the quantum
of compensation in the case of
clinical trail related serious adverse
events of injury other than deaths
occurring during clinical trial :
 The independent expert committee constituted for
examination of SAE of deaths has already devised
a formulae to determine the compensation in case
of clinical trail related death i.e.
COMPENSATION=(B*F*R)/99.37
Where, B = Base amount (i.e. 8 lacs)
F = Factor depending on the age of the
subject
R = Risk Factor depending on the
seriousness and severity of the disease, presence of
co-morbidity and duration of disease of the subject at
the time of enrolment in the clinical trial between a
scale of 0.5 to 4 as under ,
• Terminally ill patient (expected survival not more
than (NMT) 6 months)
• Patient with high risk (expected survival between 6
to 4 months)
• patient with moderate risk.
• patient with mild risk
• Healthy Volunteers or subject of no risk
 However, in case of patients whose expected mortality is 90
% or more within 30 days, a fixed amount of Rs. 2 lacs should
be given.
 The apex committee and the technical committee in its first
meeting held on 4,marcg,2014, discussed various criteria that
could be considered to determine the quantum of
compensation in clinical trial related SAE.
 The committee opened the for calculation of quantum of
compensation in such cases the guiding principle may be
linked to the criteria considered for calculation of
compensation in case of death .
 Considering the definition of SAE, following squeal other than
death are possible in a clinical trail subject , in which the
subject shall be entitled for compensation in case the SAE is
related to clinical trail.
1. A permanent disability
2. Congenital anomaly or birth defect
3. Chronic life-threating disease or
4. Reversible SAE in case it is resolved
1. In case of permanent disability :
The quantum compensation in case of 100% disability
should be 90% of the compensation which would have
been due for payment to the nominee in case of death of
the subject. The quantum for less than 100% disability will
be proportional to the actual percentage disability the
subject has suffered.
Accordingly, committee arrived at the following formula:
COMPENSATION=(C*D*90)/(100*100)
Where, D= percentage disability the subject has suffered.
C=quantum of compensation which would have
been due for payment to the subject’s nominee in case of
death of the subject.
2. In case of SAE causing life-threating disease :
The quantum of compensation should be linked to
the number of days of hospitalization of the subject.
The compensation per day of hospitalisation should
be equal to the wage loss. The wage loss per day
should be calculated based upon the minimum wage
of the unskilled worker.
Accordingly, the committee arrived the following
formula,
COMPENSTION=2*W*N
Where, W= minimum wage per day of the unskilled
worker(in Delhi)
N= number of days of hospitalization
3. In case of SAE causing of congenital
abnormality or birth defects
 The committee opined that the congenital
abnormality or birth defects in a baby may occur
due to participation of any one or both the parents
in clinical trial. Following situations may arise due
to congenital abnormality or birth defects.
1. Still birth
2. Early death due to abnormality
3. No death but deformity which can be fully
corrected through appropriate intervention.
4. Permanent disability(mental or physical)
 In case of birth defects leading to (c) and (d) above
to any child, the medical management as long as
required would be provided by the sponsor or his
representative which will be over and above the
financial compensation.
Accordingly, following formula is recommended
COMPENSATION=2*W*N
Where, W = min wages per day of workers
N = no of days of hospitalization
Thank you

More Related Content

What's hot

Informed consent process
Informed consent processInformed consent process
Informed consent processDeveraneniVinay
 
Compensation in clinical trial
Compensation in clinical trialCompensation in clinical trial
Compensation in clinical trialBhaumik Bavishi
 
Methods of randomisation in clinical trials
Methods of randomisation in clinical trialsMethods of randomisation in clinical trials
Methods of randomisation in clinical trialsAmy Mehaboob
 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfRumana Hameed
 
Documentation clinical trial
Documentation clinical trialDocumentation clinical trial
Documentation clinical trialankit sharma
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's BrochureRiyaz Gohil
 
post marketing –surveillance methods
post marketing –surveillance  methodspost marketing –surveillance  methods
post marketing –surveillance methodsAMRUTHA JOSE
 
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxE Poovarasan
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxINSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
 
Type of randomization
Type of randomizationType of randomization
Type of randomizationBharat Kumar
 
Assignment on Clinical trials
Assignment on Clinical trialsAssignment on Clinical trials
Assignment on Clinical trialsDeepak Kumar
 
Institutional review board/Independent ethics Committee
Institutional review board/Independent ethics CommitteeInstitutional review board/Independent ethics Committee
Institutional review board/Independent ethics CommitteeChintamBaladattaSai
 
Case report form and application
Case report  form  and  applicationCase report  form  and  application
Case report form and applicationIrene Vadakkan
 

What's hot (20)

Informed consent process
Informed consent processInformed consent process
Informed consent process
 
Unit 1 pharmacoepidemiology
Unit 1 pharmacoepidemiologyUnit 1 pharmacoepidemiology
Unit 1 pharmacoepidemiology
 
INFORMED CONSENT FORM
INFORMED CONSENT FORMINFORMED CONSENT FORM
INFORMED CONSENT FORM
 
Compensation in clinical trial
Compensation in clinical trialCompensation in clinical trial
Compensation in clinical trial
 
Methods of randomisation in clinical trials
Methods of randomisation in clinical trialsMethods of randomisation in clinical trials
Methods of randomisation in clinical trials
 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crf
 
Microdosing
MicrodosingMicrodosing
Microdosing
 
Randomisation
RandomisationRandomisation
Randomisation
 
Spontaneous Reporting System
Spontaneous Reporting SystemSpontaneous Reporting System
Spontaneous Reporting System
 
Phase 1 clinical trial
Phase 1 clinical trialPhase 1 clinical trial
Phase 1 clinical trial
 
Documentation clinical trial
Documentation clinical trialDocumentation clinical trial
Documentation clinical trial
 
Investigator's Brochure
Investigator's BrochureInvestigator's Brochure
Investigator's Brochure
 
post marketing –surveillance methods
post marketing –surveillance  methodspost marketing –surveillance  methods
post marketing –surveillance methods
 
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptxROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
ROLES AND RESPONSIBLITIES OF CLINICAL TRIAL PERSONNEL-INVESTIGATOR.pptx
 
Clinical study designs
Clinical study designsClinical study designs
Clinical study designs
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxINSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
 
Type of randomization
Type of randomizationType of randomization
Type of randomization
 
Assignment on Clinical trials
Assignment on Clinical trialsAssignment on Clinical trials
Assignment on Clinical trials
 
Institutional review board/Independent ethics Committee
Institutional review board/Independent ethics CommitteeInstitutional review board/Independent ethics Committee
Institutional review board/Independent ethics Committee
 
Case report form and application
Case report  form  and  applicationCase report  form  and  application
Case report form and application
 

Viewers also liked

Clinical trails
Clinical trailsClinical trails
Clinical trailsGaurav Kr
 
Ethical Considerations In Clinical Trials
Ethical  Considerations In  Clinical  TrialsEthical  Considerations In  Clinical  Trials
Ethical Considerations In Clinical Trialskrathishbopanna
 
Ethical issues in research
Ethical issues in researchEthical issues in research
Ethical issues in researchR.Harish Kumar
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentKarun Kumar
 
Ethics In Research
Ethics In ResearchEthics In Research
Ethics In ResearchGrant Heller
 
What Makes Great Infographics
What Makes Great InfographicsWhat Makes Great Infographics
What Makes Great InfographicsSlideShare
 
Masters of SlideShare
Masters of SlideShareMasters of SlideShare
Masters of SlideShareKapost
 
STOP! VIEW THIS! 10-Step Checklist When Uploading to Slideshare
STOP! VIEW THIS! 10-Step Checklist When Uploading to SlideshareSTOP! VIEW THIS! 10-Step Checklist When Uploading to Slideshare
STOP! VIEW THIS! 10-Step Checklist When Uploading to SlideshareEmpowered Presentations
 
10 Ways to Win at SlideShare SEO & Presentation Optimization
10 Ways to Win at SlideShare SEO & Presentation Optimization10 Ways to Win at SlideShare SEO & Presentation Optimization
10 Ways to Win at SlideShare SEO & Presentation OptimizationOneupweb
 
How To Get More From SlideShare - Super-Simple Tips For Content Marketing
How To Get More From SlideShare - Super-Simple Tips For Content MarketingHow To Get More From SlideShare - Super-Simple Tips For Content Marketing
How To Get More From SlideShare - Super-Simple Tips For Content MarketingContent Marketing Institute
 
How to Make Awesome SlideShares: Tips & Tricks
How to Make Awesome SlideShares: Tips & TricksHow to Make Awesome SlideShares: Tips & Tricks
How to Make Awesome SlideShares: Tips & TricksSlideShare
 

Viewers also liked (14)

Clinical trails
Clinical trailsClinical trails
Clinical trails
 
Clinical Trial Phases
Clinical Trial PhasesClinical Trial Phases
Clinical Trial Phases
 
Ethical Considerations In Clinical Trials
Ethical  Considerations In  Clinical  TrialsEthical  Considerations In  Clinical  Trials
Ethical Considerations In Clinical Trials
 
Ethical issues in research
Ethical issues in researchEthical issues in research
Ethical issues in research
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Ethics In Research
Ethics In ResearchEthics In Research
Ethics In Research
 
Clinical Trials - An Introduction
Clinical Trials - An IntroductionClinical Trials - An Introduction
Clinical Trials - An Introduction
 
What Makes Great Infographics
What Makes Great InfographicsWhat Makes Great Infographics
What Makes Great Infographics
 
Masters of SlideShare
Masters of SlideShareMasters of SlideShare
Masters of SlideShare
 
STOP! VIEW THIS! 10-Step Checklist When Uploading to Slideshare
STOP! VIEW THIS! 10-Step Checklist When Uploading to SlideshareSTOP! VIEW THIS! 10-Step Checklist When Uploading to Slideshare
STOP! VIEW THIS! 10-Step Checklist When Uploading to Slideshare
 
You Suck At PowerPoint!
You Suck At PowerPoint!You Suck At PowerPoint!
You Suck At PowerPoint!
 
10 Ways to Win at SlideShare SEO & Presentation Optimization
10 Ways to Win at SlideShare SEO & Presentation Optimization10 Ways to Win at SlideShare SEO & Presentation Optimization
10 Ways to Win at SlideShare SEO & Presentation Optimization
 
How To Get More From SlideShare - Super-Simple Tips For Content Marketing
How To Get More From SlideShare - Super-Simple Tips For Content MarketingHow To Get More From SlideShare - Super-Simple Tips For Content Marketing
How To Get More From SlideShare - Super-Simple Tips For Content Marketing
 
How to Make Awesome SlideShares: Tips & Tricks
How to Make Awesome SlideShares: Tips & TricksHow to Make Awesome SlideShares: Tips & Tricks
How to Make Awesome SlideShares: Tips & Tricks
 

Similar to Compensation given in clinical trial

Compensation guidelines in clinical trials by sourabh kosey
Compensation guidelines in clinical trials by sourabh koseyCompensation guidelines in clinical trials by sourabh kosey
Compensation guidelines in clinical trials by sourabh koseysopi_1234
 
SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019Shweta Lal
 
Safety reporting of a clinical trial
Safety reporting of a clinical trialSafety reporting of a clinical trial
Safety reporting of a clinical trialGOURIPRIYA L S
 
Health insurance
Health insuranceHealth insurance
Health insurancePrem Lata
 
Requirement to clinical study
Requirement to clinical studyRequirement to clinical study
Requirement to clinical studyDhanshreeBhattad
 
Better Life Insurance Risk Assessment by Leveraging Medical Innovations
Better Life Insurance Risk Assessment by Leveraging Medical InnovationsBetter Life Insurance Risk Assessment by Leveraging Medical Innovations
Better Life Insurance Risk Assessment by Leveraging Medical InnovationsCognizant
 
What is Surakshit Loan Bima ?
What is Surakshit Loan Bima ?What is Surakshit Loan Bima ?
What is Surakshit Loan Bima ?ColinGenerali
 
Arogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future Generali Arogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future Generali ColinGenerali
 
Arogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future GeneraliArogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future GeneraliColinGenerali
 
Insurance, compensation and indemnification of trial subjects
Insurance, compensation and indemnification of trial subjectsInsurance, compensation and indemnification of trial subjects
Insurance, compensation and indemnification of trial subjectsJyotsna Patil
 
Discharge , referral and death summary
Discharge , referral and death summary Discharge , referral and death summary
Discharge , referral and death summary Dr Mubashir Bashir
 
Apollo optima restore presentation
Apollo optima restore  presentationApollo optima restore  presentation
Apollo optima restore presentationRajesh Bhutra
 
Star Health Comprehensive Policy
Star Health Comprehensive PolicyStar Health Comprehensive Policy
Star Health Comprehensive PolicyDony Manuel
 
Medisep insurance policy , new kerala government insurance policy for govrnm...
Medisep insurance policy , new  kerala government insurance policy for govrnm...Medisep insurance policy , new  kerala government insurance policy for govrnm...
Medisep insurance policy , new kerala government insurance policy for govrnm...LinshaLichu1
 

Similar to Compensation given in clinical trial (20)

Compensation guidelines in clinical trials by sourabh kosey
Compensation guidelines in clinical trials by sourabh koseyCompensation guidelines in clinical trials by sourabh kosey
Compensation guidelines in clinical trials by sourabh kosey
 
Chapter vi compensation-sriharsha.ch
Chapter vi compensation-sriharsha.chChapter vi compensation-sriharsha.ch
Chapter vi compensation-sriharsha.ch
 
Compensation
CompensationCompensation
Compensation
 
SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019SAE REPORTING TIMELINE AND COMPENSATION 2019
SAE REPORTING TIMELINE AND COMPENSATION 2019
 
Safety reporting of a clinical trial
Safety reporting of a clinical trialSafety reporting of a clinical trial
Safety reporting of a clinical trial
 
Health insurance
Health insuranceHealth insurance
Health insurance
 
Requirement to clinical study
Requirement to clinical studyRequirement to clinical study
Requirement to clinical study
 
Better Life Insurance Risk Assessment by Leveraging Medical Innovations
Better Life Insurance Risk Assessment by Leveraging Medical InnovationsBetter Life Insurance Risk Assessment by Leveraging Medical Innovations
Better Life Insurance Risk Assessment by Leveraging Medical Innovations
 
What is Surakshit Loan Bima ?
What is Surakshit Loan Bima ?What is Surakshit Loan Bima ?
What is Surakshit Loan Bima ?
 
Arogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future Generali Arogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future Generali
 
Arogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future GeneraliArogya Sanjeevani Policy From Future Generali
Arogya Sanjeevani Policy From Future Generali
 
Insurance, compensation and indemnification of trial subjects
Insurance, compensation and indemnification of trial subjectsInsurance, compensation and indemnification of trial subjects
Insurance, compensation and indemnification of trial subjects
 
Eastzone medico legal services pv1 ggi
Eastzone medico legal services pv1 ggiEastzone medico legal services pv1 ggi
Eastzone medico legal services pv1 ggi
 
Eastzone medico legal services pvT.LTD
Eastzone medico legal services pvT.LTDEastzone medico legal services pvT.LTD
Eastzone medico legal services pvT.LTD
 
Discharge , referral and death summary
Discharge , referral and death summary Discharge , referral and death summary
Discharge , referral and death summary
 
Apollo optima restore revision
Apollo optima restore  revisionApollo optima restore  revision
Apollo optima restore revision
 
Apollo optima restore presentation
Apollo optima restore  presentationApollo optima restore  presentation
Apollo optima restore presentation
 
Star Health Comprehensive Policy
Star Health Comprehensive PolicyStar Health Comprehensive Policy
Star Health Comprehensive Policy
 
sterilisation operation insurance india
sterilisation operation insurance indiasterilisation operation insurance india
sterilisation operation insurance india
 
Medisep insurance policy , new kerala government insurance policy for govrnm...
Medisep insurance policy , new  kerala government insurance policy for govrnm...Medisep insurance policy , new  kerala government insurance policy for govrnm...
Medisep insurance policy , new kerala government insurance policy for govrnm...
 

Recently uploaded

Work, Energy and Power for class 10 ICSE Physics
Work, Energy and Power for class 10 ICSE PhysicsWork, Energy and Power for class 10 ICSE Physics
Work, Energy and Power for class 10 ICSE Physicsvishikhakeshava1
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​kaibalyasahoo82800
 
Analytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdfAnalytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdfSwapnil Therkar
 
Artificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PArtificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PPRINCE C P
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...Sérgio Sacani
 
Disentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOSTDisentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOSTSérgio Sacani
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...Sérgio Sacani
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxAleenaTreesaSaji
 
Luciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxLuciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxAleenaTreesaSaji
 
Orientation, design and principles of polyhouse
Orientation, design and principles of polyhouseOrientation, design and principles of polyhouse
Orientation, design and principles of polyhousejana861314
 
Scheme-of-Work-Science-Stage-4 cambridge science.docx
Scheme-of-Work-Science-Stage-4 cambridge science.docxScheme-of-Work-Science-Stage-4 cambridge science.docx
Scheme-of-Work-Science-Stage-4 cambridge science.docxyaramohamed343013
 
Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)Jshifa
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...jana861314
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real timeSatoshi NAKAHIRA
 
Animal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptxAnimal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptxUmerFayaz5
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxAArockiyaNisha
 
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxSOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxkessiyaTpeter
 
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.aasikanpl
 
Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsAArockiyaNisha
 
A relative description on Sonoporation.pdf
A relative description on Sonoporation.pdfA relative description on Sonoporation.pdf
A relative description on Sonoporation.pdfnehabiju2046
 

Recently uploaded (20)

Work, Energy and Power for class 10 ICSE Physics
Work, Energy and Power for class 10 ICSE PhysicsWork, Energy and Power for class 10 ICSE Physics
Work, Energy and Power for class 10 ICSE Physics
 
Nanoparticles synthesis and characterization​ ​
Nanoparticles synthesis and characterization​  ​Nanoparticles synthesis and characterization​  ​
Nanoparticles synthesis and characterization​ ​
 
Analytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdfAnalytical Profile of Coleus Forskohlii | Forskolin .pdf
Analytical Profile of Coleus Forskohlii | Forskolin .pdf
 
Artificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C PArtificial Intelligence In Microbiology by Dr. Prince C P
Artificial Intelligence In Microbiology by Dr. Prince C P
 
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
All-domain Anomaly Resolution Office U.S. Department of Defense (U) Case: “Eg...
 
Disentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOSTDisentangling the origin of chemical differences using GHOST
Disentangling the origin of chemical differences using GHOST
 
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
PossibleEoarcheanRecordsoftheGeomagneticFieldPreservedintheIsuaSupracrustalBe...
 
GFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptxGFP in rDNA Technology (Biotechnology).pptx
GFP in rDNA Technology (Biotechnology).pptx
 
Luciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptxLuciferase in rDNA technology (biotechnology).pptx
Luciferase in rDNA technology (biotechnology).pptx
 
Orientation, design and principles of polyhouse
Orientation, design and principles of polyhouseOrientation, design and principles of polyhouse
Orientation, design and principles of polyhouse
 
Scheme-of-Work-Science-Stage-4 cambridge science.docx
Scheme-of-Work-Science-Stage-4 cambridge science.docxScheme-of-Work-Science-Stage-4 cambridge science.docx
Scheme-of-Work-Science-Stage-4 cambridge science.docx
 
Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)Recombination DNA Technology (Microinjection)
Recombination DNA Technology (Microinjection)
 
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
Traditional Agroforestry System in India- Shifting Cultivation, Taungya, Home...
 
Grafana in space: Monitoring Japan's SLIM moon lander in real time
Grafana in space: Monitoring Japan's SLIM moon lander  in real timeGrafana in space: Monitoring Japan's SLIM moon lander  in real time
Grafana in space: Monitoring Japan's SLIM moon lander in real time
 
Animal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptxAnimal Communication- Auditory and Visual.pptx
Animal Communication- Auditory and Visual.pptx
 
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptxPhysiochemical properties of nanomaterials and its nanotoxicity.pptx
Physiochemical properties of nanomaterials and its nanotoxicity.pptx
 
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptxSOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
SOLUBLE PATTERN RECOGNITION RECEPTORS.pptx
 
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
Call Girls in Munirka Delhi 💯Call Us 🔝9953322196🔝 💯Escort.
 
Natural Polymer Based Nanomaterials
Natural Polymer Based NanomaterialsNatural Polymer Based Nanomaterials
Natural Polymer Based Nanomaterials
 
A relative description on Sonoporation.pdf
A relative description on Sonoporation.pdfA relative description on Sonoporation.pdf
A relative description on Sonoporation.pdf
 

Compensation given in clinical trial

  • 1. Compensation Given In Clinical Trail  Presented By : Neha Singh M.pharm 1st year Clinical Research
  • 2.  As per rule 122 DAB of drug and cosmetics rule 1945, in case of clinical trial related injury other than death, the trial subject is entitled to pay for financial compensation. The sponsor or his representative is required to pay the financial compensation as per the order of DCGI. As per the rule, the financial compensation will be over and above the expenses incurred on the medical management of the trial subject.  The appendix X11 of schedule Y of D&C rules prescribes the procedure for processing the report of the serious adverse events including the death to arrive at the cause of death/injury to the subject and to decide the quantum of the compensation.
  • 3.  The independent expert committee constituted for examination od sae of death has already devised a formulae being followed for determining the quantum of compensation in case of clinical trail related death.  Another committee was constituted in march 2014 under the chairmanship of shri R.K Jain, the additional secretory and director general (CGHS), ministry of health & family welfare, government of India to deliberate and work out a formulae to be followed to determine the quantum of compensation in case of clinical trial related injury.
  • 4. Compensation formulae (clinical trial)  As per the rule , the financial compensation will be over and above the expenses incurred on the medical management of the trial subject.  In case of clinical trial related sae of death, the DCGI will decide the quantum of compensation after considering the recommendation of independent expert committee constituted for the purpose.  The DCGI will decide the quantum of compensation considering the report of the investigator, sponsor, and the ethics committee .
  • 5.  Formulae to determine the quantum of compensation in the case of clinical trail related serious adverse events of injury other than deaths occurring during clinical trial :  The independent expert committee constituted for examination of SAE of deaths has already devised a formulae to determine the compensation in case of clinical trail related death i.e. COMPENSATION=(B*F*R)/99.37
  • 6. Where, B = Base amount (i.e. 8 lacs) F = Factor depending on the age of the subject R = Risk Factor depending on the seriousness and severity of the disease, presence of co-morbidity and duration of disease of the subject at the time of enrolment in the clinical trial between a scale of 0.5 to 4 as under , • Terminally ill patient (expected survival not more than (NMT) 6 months) • Patient with high risk (expected survival between 6 to 4 months) • patient with moderate risk. • patient with mild risk • Healthy Volunteers or subject of no risk
  • 7.  However, in case of patients whose expected mortality is 90 % or more within 30 days, a fixed amount of Rs. 2 lacs should be given.  The apex committee and the technical committee in its first meeting held on 4,marcg,2014, discussed various criteria that could be considered to determine the quantum of compensation in clinical trial related SAE.  The committee opened the for calculation of quantum of compensation in such cases the guiding principle may be linked to the criteria considered for calculation of compensation in case of death .  Considering the definition of SAE, following squeal other than death are possible in a clinical trail subject , in which the subject shall be entitled for compensation in case the SAE is related to clinical trail. 1. A permanent disability 2. Congenital anomaly or birth defect 3. Chronic life-threating disease or 4. Reversible SAE in case it is resolved
  • 8. 1. In case of permanent disability : The quantum compensation in case of 100% disability should be 90% of the compensation which would have been due for payment to the nominee in case of death of the subject. The quantum for less than 100% disability will be proportional to the actual percentage disability the subject has suffered. Accordingly, committee arrived at the following formula: COMPENSATION=(C*D*90)/(100*100) Where, D= percentage disability the subject has suffered. C=quantum of compensation which would have been due for payment to the subject’s nominee in case of death of the subject.
  • 9. 2. In case of SAE causing life-threating disease : The quantum of compensation should be linked to the number of days of hospitalization of the subject. The compensation per day of hospitalisation should be equal to the wage loss. The wage loss per day should be calculated based upon the minimum wage of the unskilled worker. Accordingly, the committee arrived the following formula, COMPENSTION=2*W*N Where, W= minimum wage per day of the unskilled worker(in Delhi) N= number of days of hospitalization
  • 10. 3. In case of SAE causing of congenital abnormality or birth defects  The committee opined that the congenital abnormality or birth defects in a baby may occur due to participation of any one or both the parents in clinical trial. Following situations may arise due to congenital abnormality or birth defects. 1. Still birth 2. Early death due to abnormality 3. No death but deformity which can be fully corrected through appropriate intervention. 4. Permanent disability(mental or physical)
  • 11.  In case of birth defects leading to (c) and (d) above to any child, the medical management as long as required would be provided by the sponsor or his representative which will be over and above the financial compensation. Accordingly, following formula is recommended COMPENSATION=2*W*N Where, W = min wages per day of workers N = no of days of hospitalization